Subject(s)
Acyclovir/therapeutic use , Bacterial Infections/drug therapy , Cephalosporins/therapeutic use , Ciprofloxacin/therapeutic use , Pancreatitis/drug therapy , Virus Diseases/drug therapy , Acute Disease , Adult , Anti-Bacterial Agents/therapeutic use , Antiviral Agents/therapeutic use , Bacterial Infections/complications , Female , Humans , Male , Pancreatitis/diagnosis , Pancreatitis/etiology , Retrospective Studies , Tertiary Care Centers , Treatment Outcome , Virus Diseases/complicationsSubject(s)
Hepatitis E virus/genetics , Hepatitis E/virology , Genotype , Humans , Male , Middle Aged , Severity of Illness IndexSubject(s)
Anticoagulants/adverse effects , Gastrointestinal Hemorrhage/chemically induced , Aged , Aged, 80 and over , Antithrombins/adverse effects , Benzimidazoles/adverse effects , Dabigatran , Female , Gastrointestinal Hemorrhage/diagnosis , Humans , Male , Morpholines/adverse effects , Retrospective Studies , Rivaroxaban , Thiophenes/adverse effects , beta-Alanine/adverse effects , beta-Alanine/analogs & derivativesSubject(s)
Antiviral Agents/therapeutic use , Guanine/analogs & derivatives , Hepatitis B, Chronic/complications , Hepatitis B, Chronic/drug therapy , Hepatitis C, Chronic/complications , Hepatitis C, Chronic/drug therapy , Interferon-alpha/therapeutic use , Polyethylene Glycols/therapeutic use , Ribavirin/therapeutic use , Humans , MaleSubject(s)
Adrenal Gland Neoplasms/secondary , Adrenal Glands/pathology , Carcinoma, Hepatocellular/drug therapy , Liver Neoplasms/drug therapy , Niacinamide/analogs & derivatives , Phenylurea Compounds/therapeutic use , Adrenal Gland Diseases/chemically induced , Adrenal Gland Diseases/diagnosis , Adrenal Gland Neoplasms/pathology , Adrenal Glands/drug effects , Antineoplastic Agents/adverse effects , Antineoplastic Agents/therapeutic use , Carcinoma, Hepatocellular/pathology , Hemorrhage/chemically induced , Hemorrhage/diagnosis , Humans , Liver Neoplasms/pathology , Male , Middle Aged , Necrosis/chemically induced , Necrosis/diagnosis , Niacinamide/adverse effects , Niacinamide/therapeutic use , Phenylurea Compounds/adverse effects , SorafenibSubject(s)
Hepatitis E virus/genetics , Hepatitis E/diagnosis , Adult , Aged , Aged, 80 and over , Antibodies/blood , DNA, Viral/analysis , Female , France , Genotype , Hospitals, Military , Humans , Immunoglobulin G/immunology , Immunoglobulin M/immunology , Male , Middle Aged , RNA, Viral/analysis , Real-Time Polymerase Chain Reaction , Retrospective Studies , Reverse Transcriptase Polymerase Chain ReactionABSTRACT
We report the first case of leptospirosis in a patient with a travel history to Mauritius, where the disease has very occasionally been reported in local populations. Following an initial dengue-like presentation, the patient suffered pancreatic involvement and trigeminal neuralgia, which are two unusual delayed features of leptospirosis.
Subject(s)
Leptospirosis/diagnosis , Travel , Adult , France , Humans , MauritiusABSTRACT
Eosinophil accumulation in the gastrointestinal tract is a common feature of numerous disorders including mainly parasitic infection, drug-induced allergic reactions, inflammatory bowel disease, and various connective tissue disorders. Digestive tissue eosinophilia requires thorough searching for secondary causes that may be specifically treated with antibiotics, dietary and drug elimination or immunosuppressive therapy. Frequency, prognosis and therapeutic implications must guide the diagnostic course. An acute eosinophilic gastroenteritis in a 78-year-old asthmatic woman receiving celecoxib is reported. She presented later with neurologic and cutaneous features and was finally treated by methylprednisolone and cyclophosphamide. The diagnostic approach leading to a Churg-Strauss syndrome (CSS) assertion is described. We discuss the pathogenesis, the management and the potential enhancing role of celecoxib in CSS gastrointestinal involvement.
Subject(s)
Churg-Strauss Syndrome/diagnosis , Acute Disease , Aged , Churg-Strauss Syndrome/complications , Enteritis/etiology , Eosinophilia/etiology , Female , Gastritis/etiology , HumansABSTRACT
Hepatitis E is an emerging imported disease in Europa but autochthonous cases are described for some years. Extra-hepatic associated manifestations are published. We report a case of acute necrotizing pancreatitis associated with imported acute viral E hepatitis (genotype 1a) in a 26 years old French man travelling and originated from Pakistan. The outcome is favourable spontaneously in two months. This life-threatening hepatitis E related complication is unknown in Europa where genotype 3 virus strains prevail. The clinical presentation is stereotyped with the onset of pancreatitis in the second or third weeks of hepatitis evolution in an Indian male in his second or third decade infected with genotype 1 strain. No pancreatitis-related death is reported in the 13 previous reported cases.
Subject(s)
Hepatitis E/complications , Pancreatitis, Acute Necrotizing/diagnosis , Pancreatitis, Acute Necrotizing/pathology , Travel , Adult , France , Hepatitis Antibodies/blood , Humans , Immunoglobulin G/blood , Male , Pakistan , RNA, Viral/blood , Time Factors , Treatment OutcomeSubject(s)
Cardiac Output, Low/complications , Cardiac Output, Low/therapy , Cardiomyopathy, Dilated/complications , Cardiomyopathy, Dilated/therapy , Liver/blood supply , Pacemaker, Artificial , Pruritus/etiology , Pruritus/therapy , Ventricular Dysfunction, Left/complications , Ventricular Dysfunction, Left/therapy , Cardiac Output, Low/diagnosis , Cardiomyopathy, Dilated/diagnosis , Cholestasis , Diagnosis, Differential , Electrocardiography, Ambulatory , Heart Failure/complications , Heart Failure/diagnosis , Heart Failure/therapy , Humans , Magnetic Resonance Imaging , Male , Middle Aged , Ventricular Dysfunction, Left/diagnosisSubject(s)
Diarrhea/epidemiology , Foodborne Diseases/epidemiology , Gastrointestinal Diseases/epidemiology , Giardiasis/diagnosis , Military Personnel , Diarrhea/parasitology , Djibouti/epidemiology , Foodborne Diseases/parasitology , France , Gastrointestinal Diseases/parasitology , Giardiasis/epidemiology , Humans , Population Surveillance , Risk FactorsSubject(s)
Catha/adverse effects , Central Nervous System Stimulants/adverse effects , Chemical and Drug Induced Liver Injury, Chronic/etiology , Liver/drug effects , Adolescent , Adult , Africa, Eastern/ethnology , Animals , Chemical and Drug Induced Liver Injury, Chronic/ethnology , Emigrants and Immigrants , Fatal Outcome , Female , Humans , Liver/pathology , Male , Mastication , Middle Aged , Netherlands/epidemiology , Plant Leaves/chemistry , Rabbits , Substance-Related DisordersABSTRACT
INTRODUCTION: Hepatitis E virus is endemic in developing countries where it is especially lethal among pregnant women. As the circulation of goods and people grows between these countries and the industrialized nations, this virus is emerging as a cause of imported acute hepatitis in the latter, where authentic autochthonous cases also exist. OBSERVATIONS: We report two cases observed in Marseille, in men aged 27 and 81 years; no mode of contamination was detected, and both outcomes were positive. DISCUSSION: This virus is circulating in non-endemic areas (as shown by its seroprevalence, which ranges from 0.4 to 2.6%, its identification in urban sewage, and the autochthonous cases reported). This dissemination, combined with its high mortality rate, even outside pregnancy (up to 12%), show the need for systematic consideration of and an early search for the often-fleeting presence of the virus and of IgM and IgG type serum antibodies in plasma and (when necessary) feces in cases of acute hepatitis, because of their often transient nature. Prophylaxis is based on improving water hygiene and is thus more difficult in industrialized countries where the level of hygiene is already high, especially when no risk factors can be identified in the autochthonous cases. Recombinant vaccines are under development.
Subject(s)
Hepatitis E/epidemiology , Adult , Aged , Aged, 80 and over , Antibodies, Viral/blood , Communicable Diseases, Emerging/epidemiology , Early Diagnosis , Feces/virology , France/epidemiology , Hepatitis E/virology , Hepatitis E virus/immunology , Hepatitis E virus/isolation & purification , Humans , Immunoglobulin G/blood , Immunoglobulin M/blood , Liver Function Tests , Male , RNA, Viral/blood , Viremia/diagnosisABSTRACT
INTRODUCTION: Chronic viral C hepatitis can be cured by shorter treatment than recommended. It is illustrated by our two case reports. CASES: We report two cases of chronic viral C hepatitis cured by short therapy with interferon standard alone in one case and the combination of pegylated-interferon and ribavirin in the second case. Genotype was undetermined for one patient and 3a for the other. DISCUSSION: Excepted genotyping and early testing of viral load decrease during treatment (12th week), we lack early predictive factors of sustained response that could help avoid prolonged, poorly tolerated therapy in future non-responders. These observations show that the treatment duration of chronic viral C hepatitis can be shortened in selected patients, who should be identified as soon as possible after the beginning of the treatment.